|HAI LALA AT TATAUS009833461B2 TAI MALAND WITH (12 ) United States Patent ( 10 ) Patent No. : US 9 ,833 ,461 B2 Modi ( 45 ) Date of Patent: Dec . 5 , 2017 ( 54 ) THERAPEUTIC COMPOSITIONS (52 ) U . S . CI. COMPRISING CANNABIDIOL AND CPC . .. .. A61K 31 /573 (2013 . 01 ) ; A61K 9 /0014 CORTICOSTEROIDS (2013 .01 ) ; A61K 9 / 0053 (2013 .01 ) ; A6IK 31 /05 (2013 . 01 ) ; A61K 31/ 352 (2013 .01 ) ( 58 ) Field of Classification Search ( 71 ) Applicant: Pankaj Modi, Ancaster (CA ) CPC . .. A61K 31 /05 ; A61K 31 / 352 ; A61K 31/ 573 ; A61K 9 / 0014 ; A61K 9 /0053 ( 72 ) Inventor: Pankaj Modi, Ancaster (CA ) See application file for complete search history . ( 73 ) Assignee : CTT Pharma Inc ., Stoney Creek ( CA ) (56 ) References Cited @@ U . S . PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 8 ,623 , 401 B2 * 1 /2014 Modi .. .. .. .. A61K 9 /0056 424 /441 U . S . C . 154 ( b ) by 0 days . 2009/ 0004275 A1* 1 / 2009 Martyn .. .. .. .. A61K 9 /006 514 / 1 . 1 ( 21 ) Appl. No .: 14 / 921, 501 2011 / 0195096 A1 * 8 / 2011 Kindler .. A61K 31 / 20 424 /400 (22 ) Filed : Oct. 23 , 2015 * cited by examiner Primary Examiner — Savitha Rao (65 ) Prior Publication Data ( 74 ) Attorney , Agent, or Firm — Gowling WLG (Canada ) US 2017 /0112855 A1 Apr . 27 , 2017 LLP (57 ) ABSTRACT ( 51 ) Int. Ci. A composition comprising a tetrahydrocannabinoid com A61K 31/ 573 ( 2006 .01 ) pound , a second cannabinoid and a corticosteroid is pro A61K 31 / 05 ( 2006 .01 ) vided . The composition is useful to treat psoriasis and A61K 31 / 352 ( 2006 .01 ) related conditions in a mammal. A61K 9 /00 ( 2006 .01 ) 14 Claims, 1 Drawing Sheet 1 ) Aminoalkylindoles a ) Naphthovlindoles JWH -018 W - 073 quetempolateWI - 398 WWF - 200 WH - 081 4 -Methyl - WH- 073 JWH -015 WH - 122 WII -210 W1-019 W1-007 fjalogladolatestamentasb ) PhenylacetylindolesLalorolato2018oplelapte JWH - 250 WH - 203 c ) Benzoylindoles RCS- 4 AV - 694 2 ) Cyclohexylphenoles lontante 3 ) Classical cannabinoids CP - 17 ,497 - C8 CP 47 , 497 HUBerei -210 U . S . Patent Dec 5 , 2017 US 9, 833, 461 B2 1 ) Aminoalkylindoles a ) Naphthoylindoles TH- 01 ??????Mi5 + 200 ??? ??? 4- ethyl- WH- 373 jH- 1 ?- W1- 21 }\ - b ) Phenylacetylindoles } :23 c ) Benzoylindoles ??- 2 ) Cyclohexylphenoles ??3 ) Classical cannabinoids # [ ] ???? £ - 797 - t CF- 17 , 497 HJ210 US 9 ,833 , 461 B2 THERAPEUTIC COMPOSITIONS thereof such as delta - 8 tetrahydrocannabinol (D8 - THC ) , COMPRISING CANNABIDIOL AND tetrahydrocannabinol acid ( THCA ) , tetrahydrocannabivarin CORTICOSTEROIDS ( THCV ) , tetrahydrocannabivarin acid ( THCVA ) , nabilone, rimonabant (SR141716 ) , JWH - 018 , JWH -073 , CP -55940 , FIELD OF THE INVENTION 5 dimethylheptylpyran , HU - 210 , HU - 331, SR144528 , WIN 55 , 212 - 2 , JWH - 133 , levonantradol and AM - 2201 . The term The present invention generally relates to therapeutic " functionally equivalent” as it relates to analogs and deriva composition comprising one or more cannabinoids , and use tives of THC refers to compounds which exhibit the same or of the composition to treat certain ailments , including pso similar therapeutic effect of THC . 10 The term “ a second cannabinoid ” refers to a cannibinoid riasis . other than a tetrahydrocannabinoid . Examples of a second BACKGROUND OF THE INVENTION cannibinoid include , but are not limited to , cannabidiol (CBD ) , cannabidiol acid (CBDA ), cannabinol (CBN ) , can Psoriasis is a chronic immune -mediated disease that gen nabigerol ( CBG ), cannabigerol acid (CBGA ), cannabidi erally appears on the skin . It occurs when the immune 15 varin (CBDV ) , cannabidivarin acid (CBDVA ) , cannabino system sends out faulty signals that speed up the growth varin (CBNV ) , cannabigerovarin (CBGV ) , cycle of skin cells . There are five types of psoriasis : plaque , cannabichromene (CBC ) , naphthoylindoles such as JWH guttate , inverse , pustular and erythrodermic . The most com 018 , JWH - 073 , JWH - 398 , JWH - 200 , JWH - 081, 4 -methyl mon form , plaque psoriasis , is commonly seen as red and JWH -073 , JWH -015 , JWH - 122 , JWH - 220 , JWH -019 , white hues of scaly patches appearing on the top first laver 20 JWH -007 ; phenylacetylindoles such as JWH - 250 and JWH of the epidermis ( skin ). Psoriasis is a chronic recurring 203 ; benzoylindoles such as RCS - 4 , AM -694 and WIN condition that varies in severity from minor localized 48 ,098 ; cyclohexylphenoles such as CP 47 ,497 -C8 and CP patches to complete body coverage . Fingernails and toenails 47, 497 ; and HU - 210 . FIG . 1 illustrates chemical structures are frequently affected (psoriatic nail dystrophy ) . Psoriasis of a number of these compounds. can also cause inflammation of the joints , which is known as 25 Cannabinoids may be extracted from the cannabis plant psoriatic arthritis . Between ten and forty percent off all11 using methods well - established in the art . Many of the people with psoriasis have psoriatic arthritis . The cause of cannibinoids may also be prepared using standard chemical psoriasis is not fully understood , but it is believed to have a synthetic methods. Some of these compounds are also genetic component. Various environmental factors may commercially available . aggravate psoriasis , including stress , and withdrawal of 30 The term " corticosteroid ” refers to steroid hormones that systemic corticosteroid . are produced in the adrenal cortex of vertebrates as well as There are many treatments available , but because of its the synthetic analogues of these hormones . Examples chronic recurrent nature , psoriasis is a challenge to treat. include , but are not limited to , clobetasol, betamethasone , Accordingly , it would be desirable to develop a novel haltobetasol, fluocinonide , flurandrrenolide , mometasone, composition useful to treat psoriasis and related conditions. 35 diflorasone , halcinonide , desoximetasone and fluticasone . Corticosteroids are commercially available in various forms . SUMMARY OF THE INVENTION Non - limiting examples include: Clobex Lotion / Spray Shampoo ( 0 . 05 % Clobetasol propionate ), Cormax Cream / It has now been found that a combination of a tetrahy Solution ( 0 .05 % Clobetasol propionate ) , Diprolene Oint drocannabinoid compound , a second cannabinoid and a 40 ment, 0 .05 % Augmented betamethasone , Olux E Foam , steroid are useful to treat psoriasis and related conditions . 0 .05 % Clobetasol propionate , Olux Foam , 0 .05 % Clobetasol Thus, in one aspect of the invention a composition com - propionate , Temovate Cream /Ointment / Solution , 0 . 05 % prising a tetrahydrocannabinoid compound , a second can Clobetasol propionate , Ultravate Cream /Ointment , 0 . 05 % nabinoid and a corticosteroid is provided . Halobetasol propionate , Vanos Cream , 0 . 1 % Fluocinonide, In another aspect, a method of treating psoriasis and 45 Cordran Tape , 0 .05 % Flurandrenolide, Diprolene Cream AF , related conditions in a mammal is provided comprising 0 .05 % Augmented betamethasone , Elocon Ointment, 0 . 1 % administering to the mammal a composition comprising a Mometasone furoate , Florone Ointment, 0 . 05 % Diflorasone tetrahydrocannabinoid compound , a second cannabinoid diacetate , Halog Ointment/ Cream , 0 . 1 % Halcinonide, Lidex and a corticosteroid . Cream /Gel / Ointment , 0 .05 % Fluocinonide , Psorcon E These and other aspects of the invention are described by 50 Cream , 0 . 05 % Diflorasone diacetate , Topicort Cream /Oint reference to the following FIGURE . ment, 0 . 25 % Desoximetasone , Topicort Gel, 0 .05 % Desoxi metasone, Cutivate Ointment, 0 . 005 % Fluticasone propi BRIEF DESCRIPTION OF THE FIGURE onate , Lidex - E Cream , 0 .05 % Fluocinonide , Luxiq Foam , 0 . 12 % Betamethasone valerate and Topicort LP Cream , FIG . 1 illustrates chemical structures of cannabinoid 55 0 .05 % Desoximetasone. compounds. The present composition will generally comprise the tetrahydrocannabinoid in an amount in the range of about DETAILED DESCRIPTION OF THE 1 - 10 % by wt, the second cannabinoid in an amount in the INVENTION range of about 1 - 10 % by wt and the corticosteroid in an 60 amount in the range of about 0 .01 - 10 % by wt. Thus , in one A formulation comprising a tetrahydrocannabinoid com - embodiment, the composition comprises tetrahydrocannabi pound , at least one second cannabinoid and a corticosteroid noid in an amount in the range of about 1 - 10 % by wt, e . g . is provided . between about 4 - 6 % by wt, the a second cannabinoid in an The term “ tetrahydrocannabinoid compound ” refers to a amount in the range of about 1 - 10 % by wt, e . g . between group of related compounds and analogs thereof , namely , 65 about 4 - 6 % by wt, and the corticosteroid in an amount in the delta - 9 tetrahydrocannabinol ( THC ) and functionally range of about 0 .01 - 1 % by wt. In a preferred embodiment, equivalent compounds, including analogs and derivatives the composition comprises the tetrahydrocannabinoid in an US 9 ,833 , 461 B2 amount of about 5 % by wt, the a second cannabinoid in an g um , xanthan gum and locust bean gum . In one embodi amount of about 5 % by wt and the corticosteroid in an ment, the wafer comprises PEG in an amount of less than amount of about 0 .05 % by wt. The term “ about” is used about 5 wt % . herein to mean an amount that may differ somewhat from the Various methods for making such wafers may be applied , given value, by an amount that would not be expected to 5 including the method described in U . S . Pat . No . 8 ,623 , 401, significantly